Revenue: As of FY2026 Q3, the actual value is USD 0.EPS: As of FY2026 Q3, the actual value is USD -0.38.EBIT: As of FY2026 Q3, the actual value is USD -519.72 K.Advanced Biomed Inc. operates as a single reportable segment, thus all financial metrics are presented for the company as a whole. <h4>Operational Metrics (Continuing Operations)</h4><ul><li>Net Income (Loss): For the three-month period ended March 31, 2026, the net loss was - $488,942, an improvement from a net loss of - $1,383,874 for the same period in 2025. For the nine-month period ended March 31, 2026, the net income was $5,982,078, a significant transition from a net loss of - $2,557,358 for the same period in 2025, primarily driven by a $7,346,684 gain from the disposal of subsidiaries. </li><li>Research and Development Expenses: These expenses were - $243,226 for the three months ended March 31, 2026, an 11% increase from - $219,966 in the prior year period. For the nine months ended March 31, 2026, they increased by 11% to - $665,140 from - $600,056 in the prior year period, mainly due to increased clinical development activities. </li><li>General and Administrative Expenses: For the three months ended March 31, 2026, these expenses decreased by 20% to - $276,610 from - $347,541 in the prior year period. However, for the nine months ended March 31, 2026, they increased by 36% to - $646,213 from - $475,093 in the prior year period. </li><li>Other Income (Expense), Net: This category showed an income of $30,894 for the three months ended March 31, 2026, compared to an expense of - $629,992 in the prior year period. For the nine months ended March 31, 2026, there was an income of $7,565,910, compared to an expense of - $686,957 in the prior year period, largely due to a $7,346,684 gain on disposal of subsidiaries. </li><li>Income (Loss) before Tax Expense: For the three months ended March 31, 2026, the loss before tax was - $488,942, compared to - $1,197,499 in the prior year period. For the nine months ended March 31, 2026, there was an income of $6,254,557, compared to a loss of - $1,762,106 in the prior year period. </li></ul><h4>Discontinued Operations</h4><ul><li>Loss from discontinued operations, net of tax, was - $272,479 for the nine-month period ended March 31, 2026, an improvement from - $795,252 for the same period in 2025, following the disposal of Advanced Biomed (HK) Limited in December 2025. </li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: For the nine months ended March 31, 2026, net cash used in operating activities was - $1,363,675, a significant improvement from - $4,281,093 in the prior year period. </li><li>Net Cash Used in Investing Activities: This amounted to - $15,941 for the nine months ended March 31, 2026, compared to - $11,501 in the prior year period. </li><li>Net Cash Provided by Financing Activities: This decreased to $1,031,216 for the nine months ended March 31, 2026, from $6,699,767 in the prior year period, primarily due to reduced equity financing. </li></ul><h4>Working Capital</h4><ul><li>As of March 31, 2026, the working capital surplus was $9,100,625, an increase from $3,143,443 as of June 30, 2025. </li></ul><h4>Future Outlook and Strategy</h4>Advanced Biomed Inc. anticipates continuous losses for the next two to three years, while maintaining its focus on microfluidic biochip technologies for oncology. The company is strategically pivoting towards AI-powered financial audit solutions following an acquisition in April 2026. To support these initiatives, Advanced Biomed Inc. plans to raise additional capital and seeks financial support, despite a current cash balance expected to last at least twelve months, though substantial doubt about its going concern remains.

Advanced Biomed | 10-Q: FY2026 Q3 Revenue: USD 0